Aktywnosc chinupristiny-dalfopristiny wobec erytromycyno-opornych szczepow MRSA izolowanych z materialu klinicznego

• Autorzy: Mlynarczyk G. , Mlynarczyk A. , Szymanek K. , Bilewska A. , Pupek J. , Luczak M.

Warianty tytułu

EN

MIC and MBC of quinupristin-dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens

• Języki publikacji: PL

Abstrakty

PL

Określono wartości MIC i MBC chinupristiny/dalfopristiny dla grupy szczepów Staphylococcus aureus. Porównywano wartości MIC i MBC uzyskane dla szczepów wykazujących indukcyjną ekspresję oporności na MLS-B (makrolidy, linkozamidy i streptograminy B) z wartościami uzyskanymi dla ich mutantów o ekspresji konstytutywnej.

EN

The MICs and MBCs of quinupristin/dalfopristin were determined for 22 clinical strains MRSA with inducible type of resistance to MLS-B and for 15 of their derivatives with constitutive resistance to MLS-B. For MRSA strains with inducible resistance to MLS-B the obtained results for quinupristin/ dalfopristin were: MIC50 = 0.25, MIC90 = 0.5,MBC90 = 1.0 and MBC90 = 1.0. Mutants of the same strains characterized with the following values for quinopristin/dalfopristin : MIC50=0.5, MIC90=1.5, MBC50=4.0 and MTC90=8.0.

Słowa kluczowe

PL

szczepy bakteryjne; szczepy erytromycynooporne; Staphylococcus aureus; gen erm; gen msr; oznaczanie; lancuchowa reakcja polimerazy; opornosc na klindamycyne

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2006
• Tom: 58
• Numer: 3
• Opis fizyczny: s.199-205,tab.,bibliogr.

Twórcy

autor

Mlynarczyk G.

• Akademia Medyczna w Warszawie, ul.Chalubinskiego 5, 02-004 Warszawa

autor

Mlynarczyk A.

autor

Szymanek K.

autor

Bilewska A.

autor

Pupek J.

autor

Luczak M.

Bibliografia

• 1. Allingion DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001; 23: 24-44.
• 2. Baysallar M, Kilic A, Aydogan H i inni., Linezolid and quinupristin-dalfopristin resistance in vancomycin-resistant enterocoeci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. Int J Antimicrob Agents 2004; 23: 510-2.
• 3. Caron F, Gold HS, Wennersten CB i inni. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin- dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 4: 2749-53.
• 4. Haroche J, Morvan A, Davi M i inni. Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals. J Clin Microbiol 2003; 41: 586-91.
• 5. Huang J, O 'Toole PW, Shen W i inni. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 909-17.
• 6. Jones ME, Visser MR, Klootmjk M i inni. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, Sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa- cinresistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999; 43: 421-3.
• 7. Malbruny B, Canu A, Bozdogan В i inni. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein m Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 2200-7.
• 8. Młynarczyk G, Młynarczyk A, Szymanek K, Łuczak M. Częstość występowania genów ermA, ermB, ermC i msrA/B u metycylino-opornych klinicznych szczepów Staphylococcus aureus. Med Dośw Mikrobiol 2006; 58: 183-90.
• 9. National Committee for Clinical Laboratory Standards, Wayne, Pa. Methods for determining bactericidal activity on antimicrobial agents; approved guideline, vol. 19 (M26-A), 1999.
• 10. National Committee for Clinical Laboratory Standards. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A7. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2006
• 11. Pankuch GA, Jacobs MR, Appelbaiim PC. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.Antimicrob Agents Chemother. 1998; 42: 3028-31.
• 12. Poole K. Efflux-mediated antimicrobial resistance J Antimicrob Chemother 2005; 56: 20-51
• 13. Roberts MC, Sutcliffe J, Courvalin P i inni. Nomenclature for macrolide-lincosamide-streptogra- min В resistance determinants. Antimicrob Agents Chemother 1999; 43: 2823-30.
• 14. Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P i inni. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother. 1998; 41: 349-55.
• 15. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group. J Antimicrob Chemother. 1999; 43: 783-92.
• 16. Smith PF, Booker BM, Ogundele AB, Kelchin P. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis. 2005; 52: 255-9.
• 17. Sutcliffe J, Grebe T, Tait-Kamradt A i inni. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother, 1996,40(11): 2562-66.
• 18. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/ dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43(4): 569-73.
• 19. von EiffC, Reinert RR, Kresken M i inni. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. J Clin Microbiol 2000; 38(8): 2819-23.
• 20. Werner G, Сипу C, Schmitz FJ, Witte W. Methicillin-resistant quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001 ; 39: 3586- 90